eligibility_summary
Eligibility: Adults (≥18) with histologic/cytologic NSCLC, measurable unresectable disease, PD-L1 TPS ≥1% (FDA-approved assay), progressed after frontline therapy, ECOG ≤2, adequate organ/marrow function, treated/stable or nonurgent brain mets, controlled HIV/HBV/HCV. Must use contraception, stop breastfeeding, consent. Exclude: other trials, active EBV/CMV, allergy to pembrolizumab/aztreonam/vancomycin/albuterol, pregnancy, FEV1 <25%, severe prior irAEs (incl pneumonitis), uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase I single-arm trial in advanced NSCLC testing: 1) Pembrolizumab—type: monoclonal antibody, immune checkpoint inhibitor, mechanism: blocks PD-1 on T cells to prevent PD-1/PD-L1 signaling and restore antitumor T-cell activity. 2) Aerosolized aztreonam—type: monobactam antibiotic, mechanism: inhibits gram-negative bacterial cell-wall synthesis (PBP binding). 3) Aerosolized vancomycin—type: glycopeptide antibiotic, mechanism: inhibits gram-positive bacterial cell-wall synthesis (binds D-Ala–D-Ala). Target cells/pathways: PD-1/PD-L1 checkpoint on tumor-infiltrating T cells (especially CD8+ T cells). Lung microbiota (gram-negative and gram-positive bacteria) to reduce dysbiosis/bacterial burden, aiming to modulate tumor-promoting inflammation and improve antitumor immune responses. Population: PD-L1 TPS ≥1% NSCLC post-frontline therapy.